← Back to Search

Brachytherapy

HDR Brachytherapy for Prostate Cancer

N/A
Waitlist Available
Led By Hans Chung, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-1
Staging T2-weighted, DWI- and DCE- MRI that demonstrates recurrence confined to prostate, and correlates with stereotactic transperineal biopsy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial is looking at the feasibility and toxicity of using radioactive seeds to treat localized prostate cancer that has come back (recurred). There are other options to treat this, but there is no consensus on which is the best. This study will look at whether the radioactive seed treatment is safe and effective.

Who is the study for?
Men with prostate cancer that has come back after radiation therapy, but hasn't spread outside the prostate. They should have a PSA level under 10ng/mL, a prostate size less than 50cc on ultrasound, and be in good physical shape (ECOG status 0-1). Men who've had certain other treatments or surgeries for prostate cancer or show signs of hormone-resistant cancer can't join.Check my eligibility
What is being tested?
This study is testing whole gland salvage HDR brachytherapy—a type of internal radiation where radioactive seeds are temporarily placed inside the prostate—to see if it's feasible and safe for treating localized recurrent prostate cancer.See study design
What are the potential side effects?
Potential side effects include urinary issues due to inflammation from the radioactive seeds, bowel problems, erectile dysfunction, and general discomfort at the seed implantation site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My MRI shows my prostate cancer has returned but is only in the prostate.
Select...
I have had radiation therapy for prostate cancer with specific dose ranges.
Select...
My scans show no cancer spread to my abdomen, pelvis, or bones.
Select...
My prostate is smaller than 50cc in volume.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acute GI toxicities
Acute GU toxicities
Secondary outcome measures
Acute GU symptoms
Biochemical disease free survival
Late GI toxicities
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: HDR whole gland salvage treatmentExperimental Treatment1 Intervention
Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
651 Previous Clinical Trials
1,542,659 Total Patients Enrolled
34 Trials studying Prostate Cancer
12,262 Patients Enrolled for Prostate Cancer
Hans Chung, MDPrincipal InvestigatorOdette Cancer Centre, Sunnybrook Health Sciences Centre
1 Previous Clinical Trials
60 Total Patients Enrolled
1 Trials studying Prostate Cancer
60 Patients Enrolled for Prostate Cancer

Media Library

HDR brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02560181 — N/A
Prostate Cancer Research Study Groups: HDR whole gland salvage treatment
Prostate Cancer Clinical Trial 2023: HDR brachytherapy Highlights & Side Effects. Trial Name: NCT02560181 — N/A
HDR brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02560181 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any sign-up opportunities for this trial currently available?

"According to clinicaltrials.gov, this particular trial is not recruiting applicants at present; the post was initially published on August 1st 2014 and last edited May 3rd 2022. However there are 2239 other trials in progress that require participants."

Answered by AI

What are the research objectives of this investigation?

"Once brachytherapy has been administered, the primary outcome assessed over a three-month time frame will be Acute Gastrointestinal Toxicities. Additionally, researchers are evaluating for Acute Genitourinary Symptoms using the American Urological Association Symptom Index Score (IPSS), Late Gastrointestinal Toxicities with NCI CTCAE v.4.0 and finally, Late GU symptoms also via IPSS scoring."

Answered by AI
~1 spots leftby Aug 2024